Research programme: proteasome inhibitors - Cytomics SystemsAlternative Names: NOPPI; REACTA
Latest Information Update: 07 Jan 2011
At a glance
- Originator Cytomics Systems
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; Proteasome inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 07 Jan 2011 Preclinical development is ongoing in France
- 05 Aug 2005 Preclinical trials in Cancer in France (unspecified route)